
AI Digest · Compass Pathways says it finished its FDA application for COMP360 psilocybin
Kalshi traders heavily favor drug developer Compass Pathways filing before December, and that view gained ground this week. Compass said on Monday it had completed its COMP360 application with the FDA, the US drug regulator. A Thursday report says the FDA is ending the priority voucher program that set a one to two month review target. The US health department has not confirmed it. Compass still expects a launch in the first half of 2027.